Clinical trials: Diabetes Type II
Type 2 Diabetes Mellitus
Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes
The purpose of this study is to evaluate the effects of dapagliflozin on kidney function, as assessed by glomerular filtration rate.
- Trial name
- NCT00976495
- Testing
- Dapagliflozin, Hydrochlorothiazide
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 154 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)
A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release (LAR) on Glucose Control (HbA1c) and Safety in Subjects with Type 2 Diabetes Mellitus Managed with Diet…
- Trial name
- NCT00308139
- Testing
- exenatide, long acting release, exenatide
- Where
- 25 sites in United States, Canada
- Volunteers
- 303 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification
This trial is conducted globally. The aim of the trial is to compare sequential addition of insulin aspart versus further dose increase with insulin degludec/liraglutide in subjects with type 2 diabetes mellitus, previously…
- Trial name
- DUAL™ (NCT02100475)
- Testing
- insulin degludec/liraglutide, insulin aspart
- Where
- 60 sites in United States, Argentina and 8 more
- Volunteers
- 31 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus
Study to investigate the safety and efficacy of long-term daily use of JARDIANCE® Tablets in Japanese patients with type 2 diabetes mellitus
- Trial name
- NCT02489942
- Testing
- Jardiance
- Where
- Japan
- Volunteers
- 8,145 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Periodontitis
Hyperbaric Oxygen Therapy as Adjunctive Therapy to Scaling and Root-planing in the Management of Periodontitis in Patients With Type 2 Diabetes
Diabetes and Periodontitis are both prevalent diseases affecting millions of Americans. Periodontitis is prevalent among Diabetics.
- Trial name
- NCT02671136
- Testing
- Hyperbaric Oxygen therapy, Conventional Wound Therapies
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Loma Linda University
Diabetes Mellitus, Type 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus
This study will consist of multiple ascending oral doses in up to 3 groups, for 29 days.
- Trial name
- NCT02445911
- Testing
- KQ-791
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- Kaneq Bioscience Limited
Type 2 Diabetes
TEEN HEED: An Adolescent Diabetes Prevention Intervention Incorporating Novel Mobile Health Technologies
The number of youth with type 2 diabetes in the U.S. is projected to increase by a staggering 49 percent by 2050, with higher rates among minority youth.
- Trial name
- NCT05560386
- Testing
- Text messaging, Virtual workshop
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Diabetes Type 2
Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus
Randomized, double-blind, placebo-controlled, parallel group study.
- Trial name
- NCT02496000
- Testing
- ORMD-0801
- Where
- 34 sites in United States
- Volunteers
- 188 people
- Sponsor
- Oramed, Ltd.
Diabetes, Diabetes Mellitus, Type 2
Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to investigate the dose-response relationship of once-daily dosing of three dose levels (3, 7 and 14 mg) of oral semaglutide versus placebo as monotherapy on glycaemic…
- Trial name
- PIONEER 9 (NCT03018028)
- Testing
- Semaglutide, Liraglutide
- Where
- 16 sites in Japan
- Volunteers
- 243 people
- Sponsor
- Novo Nordisk A/S
Diabetic Kidney Disease, Hyperuricemia
Uric Acid Lowering Trial in Youth Onset T2D
Adolescents and young adults with youth-onset type 2 diabetes (T2D) are disproportionally impacted by hyperuricemia compared to non-diabetic peers and youth with type 1 diabetes (T1D).
- Conditions
- Diabetic Kidney Disease, Hyperuricemia, Diabetes, Diabetes Mellitus, Type 2
- Trial name
- ULTRA-T2D (NCT03899883)
- Testing
- Pegloticase 8 MG/ML [Krystexxa]
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Colorado, Denver
Diabetes Mellitus, Type 2, Renal Impairment
STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT
This study will characterize the effect of varying degrees of renal impairment on the pharmacokinetics (PK), safety and tolerability of a single oral dose of PF- 06882961 compared with participants with normal renal function.
- Conditions
- Diabetes Mellitus, Type 2, Renal Impairment, Healthy
- Trial name
- NCT04616027
- Testing
- PF-06882961 20 mg
- Where
- 3 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)
To demonstrate bioequivalence of a 2.5 mg saxagliptin/500 mg metformin (glucophage) immediate release (IR) fixed dose combination (FDC) tablet to the 2.5 mg saxagliptin tablet and 500 mg metformin IR tablet co-administered to…
- Trial name
- NCT00899470
- Testing
- Co-administration of Saxagliptin and Metformin IR, Fasted, Saxagliptin/Metformin, Fasting, Co-administration of Saxagliptin and Metformin IR, Fed
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus (MK-0000-253)
This study aims to assess how glimepiride affects the recovery from hypoglycemia in participants with type 2 diabetes mellitus. The primary objective is to estimate the time taken by participants to recover from hypoglycemia to…
- Trial name
- NCT01614769
- Testing
- Glimepiride 2 mg, Glimepiride 4 mg, Hypoglycemic Clamp
- Volunteers
- 10 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study of the Current Medical Practice and Outcomes in the Treatment of Type 2 Diabetes Mellitus in an Office Setting (MK-0431-199)
The purpose of this study is to collect information of the risk profile of patients with type 2 diabetes mellitus, their treatment concerning meeting the guidelines for treatment of diabetic patients type 2 published by the…
- Trial name
- SIRTA (NCT01409213)
- Volunteers
- 1,523 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
The aim of this study is to investigate the efficacy, safety and tolerability of BI 10773 compared to placebo and sitagliptin given for 24 weeks as monotherapy in patients with T2DM with insufficient glycaemic control.
- Trial name
- NCT01177813
- Testing
- BI 10773, BI 10773 open label
- Where
- 124 sites in United States, Belgium and 7 more
- Volunteers
- 986 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes
This study will investigate how the body processes nasal glucagon and the effect of nasal glucagon on the body. After an 8-hour overnight fast and 4 hours after the start of a low-carbohydrate breakfast, the study drug will be…
- Trial name
- NCT02806960
- Testing
- Nasal Glucagon
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
Diabetic Kidney Disease
Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease
The purpose of this study is to determine whether BMS-813160 will reduce the amount of protein loss in the urine of subjects with type 2 diabetes and diabetic kidney disease
- Trial name
- NCT01752985
- Testing
- BMS-813160
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 319 people
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes Mellitus
Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)
This study will establish that the MK0431 100 mg anhydrous formulation tablets are bioequivalent to the MK0431 100 mg monohydrate final market image (FMI) tablets.
- Trial name
- NCT00944450
- Testing
- Sitagliptin phosphate anhydrous formulation, Comparator: sitagliptin phosphate monohydrate form
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes
This study will compare the effect of semaglutide once weekly to insulin aspart 3 times daily as add on to metformin and insulin glargine in people with type 2 diabetes.
- Trial name
- SUSTAIN 11 (NCT03689374)
- Testing
- Semaglutide, Insulin aspart, Insulin glargine U100
- Where
- 210 sites in Bosnia and Herzegovina, Bulgaria and 19 more
- Volunteers
- 2,274 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Hypertension
The Medication Metronome Project - Study to Facilitate Follow-up Testing Resulting From Prescribed Medications to Improve Patient Safety and Care
This project tests a model of chronic disease medication management in which the decision to initiate or adjust medical therapy is directly linked to a sequence of subsequent clinical actions (e.g.
- Conditions
- Diabetes Mellitus, Type 2, Hypertension, Hyperlipidemia
- Trial name
- NCT01586897
- Testing
- Medication Metronome, Usual Care
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Massachusetts General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.